



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Multimorbidity and out-of-pocket expenditure on medicine in Europe

Citation for published version:

Palladino, R, Pan, T, Mercer, SW, Atun, R, McPake, B, Rubba, F, Triassi, M & Tayu Lee, J 2023, 'Multimorbidity and out-of-pocket expenditure on medicine in Europe: longitudinal analysis of 13 European countries between 2013-2015', *Frontiers in public health*, vol. 10, 1053515, pp. 1053515. <https://doi.org/10.3389/fpubh.2022.1053515>

Digital Object Identifier (DOI):

[10.3389/fpubh.2022.1053515](https://doi.org/10.3389/fpubh.2022.1053515)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Frontiers in public health

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 **Multimorbidity and out-of-pocket expenditure on medicine in Europe:**
2 **longitudinal analysis of 13 European countries between 2013-2015**

3 Raffaele Palladino,^{1,2,3,†,*} Tianxin Pan,^{4,†} Stewart W Mercer,⁵ Rifat Atun,⁶ Barbara McPake,⁷ Fabiana
4 Rubba,² Maria Triassi,^{2,3} John Tayu Lee^{1,7}

5

6 1. Department of Primary Care and Public Health, School of Public Health, Imperial College,
7 London, the UK

8 2. Department of Public Health, University “Federico II” of Naples, Naples, Italy

9 3. Interdepartmental Research Center in Healthcare Management and Innovation in Healthcare
10 (CIRMIS), 80131 Naples, Italy

11 4. Health Economics Unit, Center for Health Policy, Melbourne School of Population and Global
12 Health, The University of Melbourne. Melbourne, Australia

13 5. Centre for Population Health Sciences, The Usher Institute, The University of Edinburgh,
14 Edinburgh, Scotland

15 6. Department of Global Health and Population, Harvard T H Chan School of Public Health and
16 Department of Global Health and Social Medicine, Harvard Medical School, Harvard
17 University, Harvard University

18 7. Nossal Institute for Global Health, Melbourne School of Population and Global Health, The
19 University of Melbourne. Melbourne, Australia

20 † the authors equally contributed to the manuscript

21 ***Correspondence:**

22 Raffaele Palladino,

23 Department of Primary Care and Public Health, Imperial College of London

24 Reynolds Building, W68RP, London

25 r.palladino@imperial.ac.uk

26 **Keywords: multimorbidity, out-of-pocket, medicines, Europe, Health Systems, Universal**
27 **Health Coverage**

28

29

30 Abstract

31 **Background:** Many European Health Systems are implementing or increasing levels of cost-sharing
32 for medicine in response to the growing constrains on public spending on health despite their
33 negative impact on population health due to delay in seeking care.

34 **Objective:** This study aims to examine the relationships between multimorbidity (two or more
35 coexisting chronic diseases, CDs), complex multimorbidity (three or more CDs impacting at least
36 three different body systems), and out-of-pocket expenditure (OOPE) for medicine across European
37 nations.

38 **Methods:** This study utilized data on participants aged 50 years and above from two recent waves of
39 the Survey of Health, Ageing, and Retirement in Europe conducted in 2013 (n=55,806) and 2015
40 (n=51,237). Pooled cross-sectional and longitudinal study designs were used, as well as a two-part
41 model, to analyse the association between multimorbidity and OOPE for medicine.

42 **Results:** The prevalence of multimorbidity was 50·4% in 2013 and 48·2% in 2015. Nearly half of
43 those with multimorbidity had complex multimorbidity. Each additional CD was associated with a
44 34% greater likelihood of incurring any OOPE for medicine (Odds ratio=1·34, 95% CI=1·31 - 1·36).
45 The average incremental OOPE for medicine was 26·4 euros for each additional CD (95% CI=25·1 -
46 27·7), and 32·1 euros for each additional body system affected (95% CI 30·6 - 33·7). In stratified
47 analyses for country-specific quartiles of household income the average incremental OOPE for
48 medicine was not significantly different across groups.

49 **Conclusion:** Between 2013 and 2015 in 13 European Health Systems increased prevalence of CDs
50 was associated with greater likelihood of having OOPE on medication and an increase in the average
51 amount spent when one occurred. Monitoring this indicator is important considering the negative
52 association with treatment adherence and subsequent effects on health.

53

54

55

56

57

58

59

60

61

62

63

64

65 INTRODUCTION

66 Multimorbidity, defined as the presence of two or more coexisting chronic diseases (CDs),(1) is on
67 the rise globally, and its prevalence is expected to rise further as the population ages (1-6). Because
68 of the high complexity of the care they require, people with multimorbidity incur greater health care
69 expenditure and poorer health outcomes, with these relationships being substantially stronger when
70 multimorbidity affects multiple body systems (7). Multimorbidity may have a disproportionate impact on
71 the poor, as studies have shown that the prevalence of multimorbidity is higher among them in high-
72 income nations, and they are more vulnerable to medical costs associated with multimorbidity (8).

73

74 While many nations throughout the world are making progress towards universal health coverage
75 (UHC), recent research have indicated that financial protection for medical costs is being eroded in
76 several European countries as a result of austerity measures and reduced public investment on health
77 (2). According to recent studies on UHC, cost sharing policies have been implemented in Europe
78 throughout the previous decade of public budget restraint, with most of the policy changes related to
79 medicine and outpatient care (2, 9). Monitoring out-of-pocket expenditure (OOPE) on healthcare
80 trends is crucial not just because of the financial burden associated with illness for individuals, but
81 also because of its impact on patients' access to health care, medication adherence, and chronic disease
82 management (2, 10-12).

83

84 Examining the influence of multimorbidity on OOPE for medicine is crucial for policy making
85 because studies have indicated that medicine accounts for the majority of OOPE for people suffering
86 from chronic conditions (13-15). According to a recent systematic study, an increase in the number of
87 chronic conditions was linked with increased OOPE on medicines (13), with the elderly population
88 being more susceptible to OOPE on medicine at all levels of multimorbidity (13, 16). Polypharmacy,
89 which is compounded by the use of single disease-centered guidelines to manage persons with
90 complex care needs, is common in people with multimorbidity and linked to an increase in OOPE on
91 medicine (17). Although recent data reported that OOPE on medicine for the general population
92 accounts for nearly or more than 20% of the health spending in many European countries, including
93 Czech Republic, Estonia, Germany, Italy, Slovenia, and Spain (18), the majority of previous
94 investigations were conducted in countries other than Europe (13), and none of these studies
95 investigated the impact of OOPE on medicine by socioeconomic groups across European nations. To
96 fill this important evidence vacuum, this study aims to investigate the relationship between
97 multimorbidity and OOPE on medicine using longitudinal national representative data from 13
98 European Health Systems from 2013 to 2015, and whether this varied by respondents'
99 socioeconomic position.

100

101 METHODS

102 Data and Sample

Multimorbidity and out-of-pocket expenditure on medicine in Europe

103 We used two waves of data from wave 5 (2013) and wave 6 (2015) of the Survey of Health, Ageing,
104 and Retirement in Europe (SHARE), a European panel database containing nationally representative
105 samples of respondents aged fifty and over from 28 European countries and Israel (19). Respondents'
106 sociodemographic factors, health status (including the presence of chronic illnesses and disability),
107 and health care use and spending are all included in the data. SHARE's methodologies have been
108 described in depth elsewhere (19). It is worth mentioning that while the SHARE dataset's fourth
109 wave covered more nations, OOPE for medicine data was not collected in that wave. Also in wave 7,
110 the bulk of respondents (80%) had missing information on their OOPE for medicine. We did not use
111 wave 8 because it was disrupted by the COVID-19 pandemic outbreak. Data from the following 13
112 countries were considered: Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany,
113 Italy, Luxembourg, Slovenia, Spain, Sweden, and Switzerland, which were preset in both waves 5
114 and 6. Residential care homes residents were excluded from our sample because they are expected to
115 have different health seeking behaviour than noninstitutionalized respondents.

116

117 In 2013 57,879 (wave 5) and in 2015 53,929 (wave 6) individuals aged 50 years and older did not
118 live in a nursing facility. 55,806 and 51,237 people, respectively, had comprehensive information on
119 the variables of interest listed below. We employed an unbalanced sample of 65,206 individuals with
120 107,043 observations from the two waves.

121

122 **Variables**

123 *Multimorbidity*

124 The main variable of interest was the number of coexisting CDs reported by each respondent. To
125 assess multimorbidity, we considered 17 CDs, including 16 self-reported health conditions (heart
126 attack/problem, hypertension, hypercholesterolemia, stroke/cerebral vascular illness, diabetes, cancer,
127 peptic ulcer, stomach or duodenal ulcer, chronic lung disease, arthritis/rheumatism, Parkinson
128 disease, cataracts, hip or femoral fracture, other fracture, osteoarthritis, Alzheimer
129 disease/dementia/organic brain syndrome/senility/other significant cognitive impairment, other
130 affective/emotional disorders), and one symptom-based health condition (depression). Participants
131 were asked to answer the following question: "Has a doctor ever told you that you had/do you
132 currently have any of the conditions listed on this card?" Clinical depression was the only chronic
133 disease that was not defined based on the answer to this question. The EURO-D scale was used to
134 measure and define it, in agreement with prior studies (1, 20), with scores of 4 or higher indicating
135 the presence of clinically significant depressive symptoms. Asthma and kidney illness were not
136 considered because they were not consistently asked about in the two waves.

137

138 Previous evidence suggested that individuals with complex multimorbidity, defined as the co-
139 occurrence of three or more chronic diseases that affect at least three different body (organ) systems
140 in one person (21, 22), have higher care needs, which might also translate into higher financial
141 burden.(17) Therefore, in our research we also assessed the presence of complex multimorbidity.
142 Using the International Classification of Diseases, 10th revision (ICD-10), CDs were further divided
143 into organ systems, with the following ten being included: neoplasms, endocrine, mental illness,

144 nervous system, eye, circulatory system, respiratory system, digestive system, musculoskeletal or
145 connective tissue, and fracture.

146

147 *Outcome variables*

148 OOPE on pharmaceuticals were the key outcome of interest. The enquiry “About how much did you
149 pay altogether for drugs in the last twelve months? (Include both doctor-prescribed and non-
150 prescription drugs)” led to OOPE on medicines. The OOPE on medicine is expressed in Euros and is
151 adjusted for inflation to the year of the latest data collection (2017) to allow comparisons across time.

152

153 *Covariates*

154 Additional study variables included age (50–59, 60–69, or 70 and older), sex (male, female), marital
155 status (married or in a civil partnership, others), residential country, educational attainment (less than
156 upper secondary, upper secondary, or tertiary education), household income per capita (in quartiles
157 within each country for each wave respectively; the poorest being Q1, the richest being Q4), [as proxy
158 of socio-economic position \(SEP\)](#).

159

160 **Statistical Analyses**

161 We first assessed the prevalence of multimorbidity and complex multimorbidity in each nation, as
162 well as by age group and socioeconomic position. In this analysis, sample weights in SHARE for
163 cross-sectional data were used to ensure that our estimates were comparable throughout time. We
164 further investigated patterns of multimorbidity and presented the percentage of people who had each
165 illness dyad.

166

167 We used two-part model to assess the connections between multimorbidity and OOPE in medicine.
168 When health expenditure represents the population as a whole, rather than just the users of health
169 care, the distributions usually display substantial skewness and have a large mass point at zero (i.e.,
170 truncated at zero) (23-25). In our sample, nearly one-third of observations have zero expenditures on
171 medicine. The health economics literature has settled on the two-part model as the best way to model
172 a dependent variable with a large mass at zero and many positive values (25, 26). Therefore, we first
173 modelled the probability that a person has any OOPE on medicine with a logit model using the full
174 sample and then estimated a generalised linear model (GLM) on the subset of people who have any
175 OOPE on medicine. Following literature (27), we used a Box- Cox test to determine which power
176 function for transforming the dependent expenditure to be closet to symmetric; and the estimated
177 coefficient was 0.06, corresponding to the natural log transformation. We used modified Park test to
178 determine the distribution family; we observed an estimated coefficient of 1.58 which suggested the
179 Gamma distribution. In summary, we use the log link and the gamma distribution for the GLM
180 model. We presented estimated adjusted odds ratios (OR) and coefficients (with 95 percent
181 confidence intervals) from first part and second part of the regression model, respectively. We further

182 estimated average incremental expenditure (in euros) on medicine (combined marginal effects from
183 both parts) of each additional CD from the model (25, 28).

184

185 Analyses were controlled for the covariates listed above. We used a pooled sample of all nations to
186 run the model, which contained dummy variables for each country. To account for the fact that some
187 people appeared in both waves, standard errors were clustered at the individual level to control for
188 serial correlation. Sub-group analysis was carried out by repeating the analysis for each
189 socioeconomic group and each country separately and we reported marginal effects of CDs on OOPE
190 on medicine. STATA 14.0 was used for all statistical analyses.

191

192 Two sets of sensitivity analysis were performed. First, instead of using continuous variables to
193 represent the number of CDs, we used a categorical variable to represent the number of conditions (0,
194 1, 2, 3, and 4 and more conditions) and repeated the primary analysis. Second, we used Cragg's
195 hurdle model for our main analysis, which has also been used in literature to deal with health
196 expenditure or outcomes with mass zeros (29, 30).

197

198 **RESULTS**

199 **Sample Characteristics**

200 We analysed 107,043 observations from 65,206 different people. 54% of our sample were female. In
201 2013, 66.9 percent of respondents were 60 years old or older, compared with 66.4 percent in 2015. In
202 2015, 60.4 percent of respondents had completed at least secondary school, and 30.8 percent were
203 employed (Table 1).

204

205 [Insert Table 1 here]

206

207 **Prevalence of multimorbidity and complex multimorbidity**

208 Figure 1 shows the prevalence of multimorbidity and complex multimorbidity in each country in
209 2013 and 2015. In 2013 and 2015, the prevalence of multimorbidity was 50.4 percent and 48.2
210 percent, respectively, and the prevalence of complex multimorbidity was 25.5 percent and 22.9
211 percent. Nearly half of individuals (49.0 percent) with multimorbidity had complex multimorbidity.
212 In 2015, the prevalence of multimorbidity ranged from 32.1 percent (Switzerland) to 53.3 percent
213 (Estonia) and ranged from 12.4 percent (Switzerland) to 26.9 percent (Estonia) for complex
214 multimorbidity. Though there was a decrease in the prevalence of multimorbidity and complex
215 multimorbidity within our full sample, five countries registered an increase (Austria, Belgium,
216 France, Slovenia and Estonia) from 2013 to 2015. Table S1 reports the prevalence of multimorbidity
217 and complex multimorbidity in each country.

218

219 [Insert Figure 1 here]

220

221 Multimorbidity is depicted in Figure 2 by age group and socioeconomic position. Multimorbidity and
222 complex multimorbidity were shown to be more common as people became older. The prevalence
223 was higher among respondents from lower socioeconomic groups within their country. Except for the
224 richest group, the prevalence of multimorbidity was comparable across other population groups
225 (between 67.3 percent and 68.5 percent) among respondents aged 70 and older. The prevalence
226 figures are presented in Table S2.

227

228 [Insert Figure 2 here]

229

230 On average, multimorbidity affected 1.7 body systems (95%CI 1.67 – 1.69) in 2013 and 1.6 body
231 systems (95%CI 1.55 – 1.57) in 2015 (Table S3), with circulatory system being the most affected
232 body system in both years (44.4%, 95%CI 44.1% - 44.8% in 2013 and 43.1%, 95%CI 42.8% - 43.5%
233 in 2015). Figure 3 depicts the prevalence of co-existing CDs from various body systems in people
234 with multimorbidity. The most common dyad was circulatory system condition and endocrine
235 condition (65.5 percent), followed by circulatory and eye condition (63.6 percent) and mental illness
236 and nervous system condition (61.5 percent).

237

238 [Insert Figure 3 here]

239

240 **Associations between multimorbidity and out-of-pocket expenditure on medicine**

241 On average, among those who occurred relevant costs, total OOPE increased from 331 to 338 euros
242 from 2013 to 2015, with more than 50% of the total OOPE spent on medicine (50.2% in 2013 and
243 52.8% in 2015). The country with the largest proportion of total OOPE spent on medicine in 2015
244 was Estonia (71.1%), while the lowest was Switzerland (16.5%; Table S4).

245 Table 2 displays the results of a two-part model that combines logit regression with GLM. According
246 to the logit, each additional CD was associated with a 34% greater likelihood of incurring OOPE on
247 medicine (OR=1.34, 95% CI=1.31 - 1.36). The GLM model suggests that each additional CD was
248 associated with an increase in OOPE spending (regression coefficient 0.15, 95% CI=0.14-0.16). We
249 found that the average incremental spending of each additional CD was 26.4 euros (95%CI 25.1 -
250 27.7), according to the mean marginal effect incorporating both portions of the two-part model.

251

252 [Insert Table 2 here]

253

254 The association between the number of CDs affecting various body systems and OOPE on medicine
255 is shown in Table 3. The effects were similar to those considering CDs but were greater in their
256 magnitude. The average extra expenditure of an additional number of body system was 32.1 euros
257 (95 %CI=30.6 - 33.7), according to the mean marginal effect.

258

259 [Insert Table 3 here]

260

261 We repeated our main analysis using a categorical variable to represent the number of CDs (0, 1, 2, 3,
262 and 4 and more conditions); the results were very comparable to those in the main analyses; and the
263 results reveal that, when compared to persons without CD, those with four or more conditions spent
264 additional 140.7 euros on medicine (Tables S5 and S6). We also used Cragg's hurdle model instead
265 of two-part model for our main analysis. The marginal effects from hurdle model that combining the
266 selection model and outcome model (25.9 euros for additional one CD on OOPE on medicine) were
267 similar compared to those of two-part model. (Tables S7 and S8)

268

269 **Associations between multimorbidity and out-of-pocket expenditure on medicine by SEP** 270 **groups and country**

271 Figure 4 shows the average incremental OOPE on medicine (i.e. marginal effects) for an additional
272 CD by economic status and country. People from the richest quartile of their country spent more
273 OOPE for medicine for each additional CD, as compared with those from the poorest quartile (Q1:
274 25.52 euros, 95%CI=23.10 – 27.95; Q2: 25.00, 95%CI=22.94 – 27.05; Q3: 26.59, 95%CI= 24.09 –
275 29.10; Q4: 29.81, 95%CI=27.27 – 32.35), although confidence intervals overlapped. Belgium,
276 Denmark, and Estonia were the countries where people spent more on OOPE on average (66.0 euros,
277 61.0 euros and 55.7 euros respectively) for each additional number of CDs, while people from France
278 and Slovenia spent much less on medicine out-of- pocket from CDs (8.9 and 9.0 euros). Trends were
279 also confirmed when considering increase in CD from different body systems (Figure 4).

280

281 [Insert Figure 4 here]

282

283 **DISCUSSION**

284 Our study is the first study to focus on the relationships between multimorbidity, complex
285 multimorbidity, and OOPE for medicine across 13 European countries. We discovered that nearly
286 half (48.2 percent) of adults aged 50 and older had multimorbidity in 2015, and 22.9 percent had
287 complex multimorbidity. Although prevalence decreased slightly from 2013 levels (50.4 percent and
288 25.5 percent, respectively), patterns varied significantly between nations, which might partially be
289 explained by the different level of integrated care model implementation for individuals with

290 complex care needs in each country (1). The prevalence was highest among those over the age of 70
291 and those with a poor socioeconomic position. An increased number of CD was associated with an
292 increased risk of experiencing OOPE on medicine and an increase in the average amount spent when
293 one occurred. The average incremental expenditure of each additional CD was 26.4 euros. Whilst the
294 marginal estimated expenditure of OOPE on medicine varied considerably across countries, no
295 significant differences were observed in stratified analyses by country-specific quartiles of household
296 income. When complex multimorbidity was included, the association between multimorbidity and
297 OOPE on medicine was considerably stronger.

298

299 Consistent with previous research demonstrating the health system impoverishment exacerbating the
300 burden of CD in European countries (1, 2, 5), our study discovered that multimorbidity is linked with
301 a substantial rise in OOPE for medication across all socioeconomic categories. However, most of the
302 previous studies focused on the effect of specific chronic conditions, whilst our study examined the
303 impact of multimorbidity, particularly complex multimorbidity.

304

305 **Strength and limitations**

306 To our knowledge the current study was the first to examine the impact of multimorbidity,
307 particularly complex multimorbidity on OOPE on medicine in older adults in Europe. Additionally,
308 our research was the first to use a panel data study methodology and to use nationally representative
309 data from 13 European nations. Several limitations merit discussion. To begin, self-reported
310 measures of CD and health care usage may have underestimated their frequency, especially among
311 older adults and those with lower socioeconomic and educational status, who are more prone to
312 underreport these variables (1, 31). Second, some of the country-specific differences we observed
313 might be explained by differences in the Health Systems, especially in regard to cost-sharing policies.
314 However, we conducted country-specific analyses for this specific reason and additionally controlled
315 pooled analyses for countries as fixed effects to remove this variability. Third, the SHARE
316 questionnaire does not contain questions regarding all CDs that are often included in clinical database
317 research (32). Additional research investigating the impact of multimorbidity associated with other
318 prevalent CDs (eg, Alzheimer's disease, and mental health problems) and chronic infectious diseases
319 (eg, TB, AIDS, long coronavirus disease) is also needed. The social patterning of multimorbidity in
320 Europe needs further study that should cover a broader variety of morbidities and more rigors
321 measurements of both mental and physical health than has been previously documented. Future
322 research with an appropriate powering will be necessary to determine the effect of multimorbidity as
323 well as what specific multimorbidity dyads and complex multimorbidity contribute the most to the
324 increasing of OOPE in general and specifically of OOPE on medicine.

325

326 **Policy implications**

327 European health systems have lagged behind in responding to the growing burden of multimorbidity
328 (1, 2, 5). Over the last few years, national and international guidelines have been produced to
329 improve care for persons with multimorbidity (33, 34) and integrated care models targeting
330 individuals with specific combinations of chronic diseases have been introduced in a number of
331 countries. However, in the majority of European nations, the quality of care for persons with multiple

Multimorbidity and out-of-pocket expenditure on medicine in Europe

332 morbidities remains suboptimal due to fragmented care pathways focused on a single condition,
333 increasing the risk of polypharmacy and associated health expenditure (17, 35). Furthermore, the
334 COVID-19 pandemic has exacerbated health system challenges by reducing integrated care pathways
335 and geriatric rehabilitation services despite increased demand (36).

336

337 Multimorbidity is related with a higher reliance on healthcare and, thus, an increased expenditure on
338 healthcare (1, 2). While new research indicates a global decline in OOPE, this is not the case for
339 OOPE as a share of income (37). Additionally, our findings indicated that OOPE on medications is
340 increasing in European countries over time. As medicine accounts for the majority of out-of-pocket
341 expenditure (13-15), monitoring this statistic is critical, considering increased OOPE on medicine is
342 connected with a larger chance of non-adherence, which has a negative effect on health (11).

343

344 While the increase in OOPE on medicine can be interpreted as further evidence of the erosion of the
345 UHC in European Health Systems, we also discovered that those with lower socioeconomic position
346 were less likely to incur OOPE on medicine. Whilst these findings might be implying that some form
347 of social protection for cost-sharing policies remains in place, we also found that the average
348 expenditure for each additional CD, estimated using marginal effects, was characterized by a positive
349 but non statistically significant gradient when moving from the poorest to the richest group. These
350 differences might be explained by several factors, which might impact the association between CD
351 and OOPE on medicine differently. First, the efficacy of social protection policies might be limited
352 without fully exempting those who are worse off from payment. Second, the most disadvantaged
353 groups might be unable to afford to pay for the medications they need, which might result in delay in
354 seeking care with negative impact on their health. These aspects warrant further research.

355 Ultimately, our findings indicating a significant increase in OOPE for medicine for individuals with
356 multimorbidity are troubling. As CDs can last a lifetime, they can impose significant financial strain
357 over time. Our findings emphasise the importance of enhancing financial protection for individuals
358 with many comorbidities, as they will face a much-increased level of OOPE for medications.

359

360 **Conclusion**

361 Although majority of the European Health Systems have yet to implement specific clinical
362 guidelines, the management of multimorbidity should be an absolute public health priority,
363 considering that over half of adults aged 50 and older in Europe have multimorbidity, and almost a
364 quarter has complex multimorbidity. We found that increased number of CDs was associated with an
365 increased risk of experiencing OOPE on medication and an increase in the average amount spent
366 when one occurred. When complex multimorbidity was included, the association between
367 multimorbidity and OOPE on medicine was considerably stronger. The average incremental OOPE
368 on medicine associated with number of CDs varied substantially across countries but not between
369 SEP groups. As medicine accounts for the majority of OOPE, monitoring this indicator is critical as it
370 can be considered as a proxy of erosion of the UHC in European Health Systems and because
371 increased OOPE on medicine is connected with a larger chance of non-adherence to treatment, which
372 has a negative effect on health.

373

374

375

376 **Figure 1. Prevalence of multimorbidity and complex multimorbidity among people ages 50 and**
377 **older in 13 European countries, 2013-2015**

378 Notes: Complex sample weight applied to the analysis. MM: multimorbidity, defined as the presence
379 of two or more chronic diseases. Complex MM: complex multimorbidity, defined as having three or
380 more chronic diseases impacting at least three different body systems in one person.

381

382 **Figure 2. Prevalence of multimorbidity (A) and complex multimorbidity (B) among people**
383 **ages 50 and older in 13 European countries, analysis in pooled sample of 2013 and 2015, by age**
384 **and socio-economic position**

385 Notes: Complex sample weights applied to the analyses. MM: multimorbidity, defined as the
386 presence of two or more of chronic diseases. Complex MM: complex multimorbidity, defined as
387 having three or more chronic diseases impacting at least three different body systems in one person.
388 Socio-economic position measured using household income per capita, in quintiles within each
389 country for each wave respectively; the poorest being Q1 =1, the richest being Q4=4.

390

391 **Figure 3. The prevalence of co-existing chronic diseases from different body systems for each**
392 **body system condition for people with multimorbidity**

393 Notes: Numbers in the bubble and bubble size represents the prevalence of co-existing chronic
394 diseases from the two corresponding body systems.

395

396 **Figure 4. Average incremental out-of-pocket expenditures on medicine for each additional**
397 **chronic diseases by economic position and country.**

398 Notes: The figure shows the average incremental out-of-pocket expenditures on medicine (i.e.
399 marginal effects) for each additional chronic disease by economic status and country. Estimates were
400 derived from a log link GLM model with gamma distribution. Socio-economic position measured
401 using household income per capita, in quintiles within each country for each wave respectively; the
402 poorest being Q1 =1, the richest being Q4=4.

403

404

405

406

Multimorbidity and out-of-pocket expenditure on medicine in Europe

407

408

409

410 **Table 1. Sample characteristics of respondents from 13 European countries**

411 Notes: Descriptive statistics were calculated using the survey weights provided.

	2013		2015	
	N	%	N	%
Age group				
50-59 years	14854	33.1%	11786	33.6%
60-69 years	19749	29.5%	18592	29.9%
70+ years	21203	37.4%	20859	36.5%
Gender				
male	24895	46.0%	22469	46.3%
female	30911	54.0%	28768	53.7%
Marital status				
other	16658	35.0%	15806	35.5%
married or in a civil partnership	39148	65.0%	35431	64.5%
Educational attainment				
less than upper secondary	21814	42.7%	19277	39.6%
upper secondary	21482	37.1%	20062	38.9%
above	12509	20.2%	11898	21.5%
Household income				
Q1	13971	26.2%	12826	25.7%
Q2	13936	24.7%	12795	24.3%

Multimorbidity and out-of-pocket expenditure on medicine in Europe

412

Q3	13953	24.6%	12809	24.4%
Q4	13946	24.6%	12806	25.5%
Country				
Austria	3965	2.5%	3068	2.6%
Germany	5433	28.1%	4214	28.5%
Sweden	4376	3.0%	3740	3.0%
Spain	6139	13.6%	4953	13.7%
Italy	4498	20.3%	4883	20.1%
France	4307	20.4%	3673	20.1%
Denmark	3926	1.7%	3554	1.7%
Switzerland	2932	2.5%	2694	2.5%
Belgium	5312	3.4%	5412	3.4%
Czech Republic	5220	3.2%	4516	3.2%
Luxembourg	1509	0.1%	1483	0.1%
Slovenia	2829	0.7%	3972	0.7%
Estonia	5360	0.4%	5075	0.4%
N	55,806		51,237	

413 **Table 2. Association between multimorbidity with OOPE on medicine among people ages 50**
414 **and older in 13 European countries between 2013-2015.**

415 Notes: Estimates obtained from two-part model that the first part is modeled through a logit model to
416 estimate the likelihood of incurring OOPE on medicine, and second part using a generalized linear
417 model with gamma distribution and log link function to model the amount of OOPE on medicine if
418 occurred. Standard errors were clustered at the individual level to control for serial correlation.
419 Margins shows combined marginal effects from both parts of the two-part model. Confidence
420 interval in parentheses. *** statistical significance at the 1% level; ** statistical significance at the
421 5% level; *, statistical significance at the 10% level. GLM: generalised linear model; CD: chronic
422 diseases; CI: confidence interval.

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

Multimorbidity and out-of-pocket expenditure on medicine in Europe

	First part Logit		Second part GLM		Overall	
	Coefficient	95% CI	Coefficient	95% CI	Margins	95% CI
Number of CDs	1.34***	(1.31 - 1.36)	0.15***	(0.14 - 0.16)	26.39***	(25.10 - 27.68)
Age groups (ref: 50-59 years)						
60-69	1.00	(0.94 - 1.08)	0.07***	(0.02 - 0.12)	7.99***	(2.50 - 13.49)
70+	0.97	(0.90 - 1.04)	0.18***	(0.13 - 0.22)	19.90***	(14.40 - 25.41)
Gender (ref: male)						
Female	1.26***	(1.19 - 1.33)	0.05**	(0.01 - 0.08)	12.06***	(7.46 - 16.65)
Marital status (ref: other)						
Married	1.06*	(1.00 - 1.13)	0.07***	(0.03 - 0.11)	9.62***	(4.92 - 14.32)
Educational attainment (ref: less than secondary school)						
Upper secondary	1.28***	(1.19 - 1.38)	0.02	(-0.03 - 0.06)	9.01***	(3.34 - 14.69)
Tertiary	1.30***	(1.19 - 1.42)	0.10***	(0.04 - 0.16)	19.67***	(12.35 - 26.99)
Socio-economics position (ref: Q1 poorest)						
Q2	1.28***	(1.20 - 1.37)	-0.04**	(-0.08 - -0.00)	2.08	(-3.05 - 7.22)
Q3	1.42***	(1.32 - 1.53)	-0.03	(-0.07 - 0.02)	6.89**	(1.11 - 12.68)
Q4	1.28***	(1.19 - 1.39)	0.05*	(0.00 - 0.09)	12.96***	(6.69 - 19.23)
Country (ref: Austria)						
Germany	1.70***	(1.55 - 1.86)	-0.61***	(-0.66 - -0.56)	-50.13***	(-57.33 - -42.92)
Sweden	3.01***	(2.71 - 3.35)	-0.43***	(-0.48 - -0.38)	-19.26***	(-26.63 - -11.89)
Spain	1.31***	(1.16 - 1.49)	-0.84***	(-0.92 - -0.76)	-72.82***	(-81.02 - -64.62)
Italy	1.25***	(1.14 - 1.38)	-0.05*	(-0.10 - 0.01)	3.48	(-5.27 - 12.22)
France	0.68***	(0.62 - 0.74)	-0.83***	(-0.90 - -0.76)	-86.26***	(-93.49 - -79.03)
Denmark	2.52***	(2.29 - 2.77)	-0.08***	(-0.13 - -0.02)	25.11***	(16.22 - 34.00)

Multimorbidity and out-of-pocket expenditure on medicine in Europe

Switzerland	0.63***	(0.57 - 0.69)	0.27***	(0.20 - 0.33)	12.38**	(1.50 - 23.26)
Belgium	3.78***	(3.40 - 4.19)	0.19***	(0.14 - 0.24)	89.91***	(79.88 - 99.94)
Czech Republic	3.62***	(3.14 - 4.18)	-0.97***	(-1.03 - -0.91)	-66.90***	(-74.15 - -59.65)
Luxembourg	1.67***	(1.47 - 1.90)	0.12***	(0.04 - 0.19)	42.99***	(28.76 - 57.23)
Slovenia	0.51***	(0.47 - 0.56)	-0.98***	(-1.06 - -0.89)	-98.54***	(-105.73 - -91.35)
Estonia	4.26***	(3.87 - 4.69)	-0.16***	(-0.21 - -0.12)	24.27***	(16.71 - 31.83)
Year						
2015	1.05**	(1.00 - 1.10)	0.00	(-0.03 - 0.03)	1.78	(-1.99 - 5.56)

444 **Table 3. Association between complex multimorbidity with OOPE on medicine among people**
445 **ages 50 and older in 13 European countries between 2013-2015.**

446 Notes: Estimates obtained from two-part model that the first part is modeled through a logit model to
447 estimate the likelihood of incurring OOPE on medicine, and second part using a generalized linear
448 model with gamma distribution and log link function to model the amount of OOPE on medicine if
449 occurred. Standard errors were clustered at the individual level to control for serial correlation.
450 Margins show combined marginal effects from both parts of the two-part model. Confidence interval
451 in parentheses. *** statistical significance at the 1% level; ** statistical significance at the 5% level;
452 *, statistical significance at the 10% level. GLM: generalised linear model; CD: chronic diseases; CI:
453 confidence interval.

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

Multimorbidity and out-of-pocket expenditure on medicine in Europe

	First part Logit		Second part GLM		Overall	
	Coefficient	95% CI	Coefficient	95% CI	Margins	95% CI
Number of CDs from different body systems	1.43***	(1.39 - 1.46)	0.18***	(0.17 - 0.20)	32.14***	(30.55 - 33.74)
Age groups (ref: 50-59 years)						
60-69	1.00	(0.93 - 1.07)	0.07***	(0.02 - 0.11)	7.48***	(1.96 - 12.99)
70+	0.95	(0.88 - 1.02)	0.17***	(0.13 - 0.22)	18.94***	(13.43 - 24.46)
Gender (ref: male)						
Female	1.25***	(1.18 - 1.32)	0.04**	(0.01 - 0.08)	11.38***	(6.77 - 15.99)
Marital status (ref: other)						
Married	1.06*	(1.00 - 1.13)	0.07***	(0.03 - 0.11)	9.71***	(5.01 - 14.41)
Educational attainment (ref: less than secondary school)						
Upper secondary	1.28***	(1.19 - 1.38)	0.02	(-0.03 - 0.06)	9.11***	(3.42 - 14.79)
Tertiary	1.30***	(1.20 - 1.42)	0.10***	(0.04 - 0.15)	19.78***	(12.49 - 27.06)
Socio-economics position (ref: Q1 poorest)						
Q2	1.28***	(1.20 - 1.37)	-0.05**	(-0.09 - -0.01)	1.60	(-3.58 - 6.78)
Q3	1.42***	(1.32 - 1.53)	-0.03	(-0.08 - 0.02)	6.32**	(0.49 - 12.15)
Q4	1.28***	(1.18 - 1.38)	0.04	(-0.01 - 0.08)	11.69***	(5.39 - 17.98)
Country (ref: Austria)						
Germany	1.68***	(1.54 - 1.84)	-0.62***	(-0.67 - -0.56)	-51.41***	(-58.67 - -44.15)
Sweden	3.00***	(2.70 - 3.33)	-0.44***	(-0.49 - -0.39)	-20.92***	(-28.33 - -13.51)
Spain	1.32***	(1.16 - 1.49)	-0.84***	(-0.92 - -0.76)	-73.54***	(-81.82 - -65.25)
Italy	1.24***	(1.13 - 1.36)	-0.06**	(-0.11 - -0.00)	1.62	(-7.17 - 10.41)
France	0.66***	(0.61 - 0.72)	-0.85***	(-0.92 - -0.78)	-88.53***	(-95.78 - -81.28)
Denmark	2.49***	(2.27 - 2.74)	-0.09***	(-0.14 - -0.03)	23.64***	(14.67 - 32.61)

Multimorbidity and out-of-pocket expenditure on medicine in Europe

Switzerland	0.62***	(0.57 - 0.69)	0.26***	(0.19 - 0.32)	10.54*	(-0.36 - 21.45)
Belgium	3.73***	(3.36 - 4.14)	0.18***	(0.13 - 0.23)	88.06***	(77.95 - 98.17)
Czech Republic	3.60***	(3.12 - 4.15)	-0.97***	(-1.03 - -0.91)	-67.70***	(-75.07 - -60.33)
Luxembourg	1.63***	(1.44 - 1.86)	0.11***	(0.03 - 0.18)	40.68***	(26.47 - 54.89)
Slovenia	0.51***	(0.47 - 0.56)	-0.99***	(-1.07 - -0.90)	-100.07***	(-107.27 - -92.87)
Estonia	4.25***	(3.87 - 4.68)	-0.16***	(-0.21 - -0.12)	24.76***	(17.12 - 32.41)
Year						
2015	1.05**	(1.01 - 1.10)	0.00	(-0.03 - 0.03)	1.83	(-1.96 - 5.61)

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491 **Author contributions**

492 RP, TP, and JTL conceived the study. RP, TP, and JTL devised the study methodology. RP and TP did the
493 formal data analysis. RP, TP, SWM, and JTL wrote the first draft of the manuscript. All authors reviewed and
494 edited the manuscript. RP and JTL supervised the study. RP had final responsibility for the decision to submit
495 for publication.

496 **Funding**

497 No funding

498 **Acknowledgments**

499 The Survey of Health, Ageing and Retirement in Europe has been funded by the European
500 Commission through FP5 (QLK6-CT-2001-00360), FP6 (SHARE-I3: RII-CT-2006-062193,
501 COMPARE: CIT5-CT-2005-028857, SHARELIFE: CIT4-CT-2006-028812), FP7 (SHARE-PREP:
502 GA N°211909, SHARE-LEAP: GA N°227822, SHARE M4: GA N°261982, DASISH: GA
503 N°283646) and Horizon 2020 (SHARE-DEV3: GA N°676536, SHARECOHESION: GA N°870628,
504 SERISS: GA N°654221, SSHOC: GA N°823782), and by the Directorate-General for Employment,
505 Social Affairs and Inclusion. Additional funding from the German Ministry of Education and
506 Research, the Max Planck Society for the Advancement of Science, the US National Institute on
507 Aging (U01_AG09740-13S2, P01_AG005842, P01_AG08291, P30_AG12815, R21_AG025169,
508 Y1-AG-4553-01, IAG_BSR06-11, OGHA_04-064, HHSN271201300071C), and from various
509 national funding sources is gratefully acknowledged.

510 Raffaele Palladino is partially supported by the National Institute for Health (NIHR) Research
511 Applied Research Collaboration (ARC) Northwest London. The views expressed in this publication
512 are those of the author(s) and not necessarily those of the NIHR or the Department of Health and
513 Social Care.

514 **Data Availability Statement**

515 Survey of Health, Ageing and Retirement in Europe (SHARE) data are accessible after registration
516 with the SHARE project at the following addresses: wave 5 (DOI:10.6103/SHARE.w5.710) and
517 wave 6 (DOI:10.6103/SHARE.w6.710).

518

519

520

521

522

523

524

525

526 **References**

- 527 1. Palladino R, Pennino F, Finbarr M, Millett C, Triassi M. Multimorbidity And Health Outcomes In
528 Older Adults In Ten European Health Systems, 2006-15. *Health Aff (Millwood)*. 2019
529 Apr;38(4):613-623. doi:10.1377/hlthaff.2018.05273. Cited in: Pubmed; PMID 30933577.
- 530
- 531 2. Palladino R, Lee JT, Hone T, Filippidis FT, Millett C. The Great Recession And Increased Cost
532 Sharing In European Health Systems. *Health Aff (Millwood)*. 2016 Jul 01;35(7):1204-13. eng. Epub
533 2016/07/08. doi:10.1377/hlthaff.2015.1170. Cited in: Pubmed; PMID 27385235.
- 534
- 535 3. Zhao Y, Atun R, Oldenburg B, McPake B, Tang S, Mercer SW, Cowling TE, Sum G, Qin VM,
536 Lee JT. Physical multimorbidity, health service use, and catastrophic health expenditure by
537 socioeconomic groups in China: an analysis of population-based panel data. *Lancet Glob Health*.
538 2020 Jun;8(6):e840-e849. Epub 2020/05/25. doi:10.1016/S2214-109X(20)30127-3. Cited in:
539 Pubmed; PMID 32446349.
- 540
- 541 4. Department of Economics and Social Affairs - Population Division. World population ageing
542 2013. New York; 2013. Report No.: 9789211515152 (paperback) : No price. United Nations.
- 543
- 544 5. Rijken M., Struckmann V., van der Heide R, Hujala A., Barbabella F., van Dinneken E., Schellevis
545 F. How to improve care for people with multimorbidity in Europe? Berlin, Germany; 2016. European
546 Observatory on Health Systems and Policies.
- 547
- 548 6. Anindya K, Ng N, Atun R, Marthias T, Zhao Y, McPake B, van Heusden A, Pan T, Lee JT. Effect
549 of multimorbidity on utilisation and out-of-pocket expenditure in Indonesia: quantile regression
550 analysis. *BMC Health Serv Res*. 2021 May 5;21(1):427. Epub 2021/05/07. doi:10.1186/s12913-021-
551 06446-9. Cited in: Pubmed; PMID 33952273.
- 552
- 553 7. Storeng SH, Vinjerui KH, Sund ER, Krokstad S. Associations between complex multimorbidity,
554 activities of daily living and mortality among older Norwegians. A prospective cohort study: the
555 HUNT Study, Norway. *BMC Geriatr*. 2020 Jan 21;20(1):21. Epub 2020/01/23. doi:10.1186/s12877-
556 020-1425-3. Cited in: Pubmed; PMID 31964341.
- 557
- 558 8. Violan C., Foguet-Boreu Q., Flores-Mateo G., Salisbury C., Blom J., Freitag M., Glynn L., Muth
559 C., Valderas J. M. Prevalence, determinants and patterns of multimorbidity in primary care: a
560 systematic review of observational studies. *PLoS One*. 2014;9(7):e102149. Epub 2014/07/23.
561 doi:10.1371/journal.pone.0102149. Cited in: Pubmed; PMID 25048354.

562

Multimorbidity and out-of-pocket expenditure on medicine in Europe

- 563 9. Jaspers L, Colpani V, Chaker L, van der Lee SJ, Muka T, Imo D, Mendis S, Chowdhury R,
564 Bramer WM, Falla A, Pazoki R, Franco OH. The global impact of non-communicable diseases on
565 households and impoverishment: a systematic review. *European Journal of Epidemiology*.
566 2014;30(3):163-188. doi:10.1007/s10654-014-9983-3.
- 567
- 568 10. Chernew M GT, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased
569 patient cost sharing on socioeconomic disparities in health care. *J Gen Intern Med*. 2008;23(8):1131-
570 6. doi:10.1007/s11606-008-0614-0.
- 571
- 572 11. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication
573 and medical utilization and spending and health. *JAMA*. 2007 Jul 4;298(1):61-9.
574 doi:10.1001/jama.298.1.61. Cited in: Pubmed; PMID 17609491.
- 575
- 576 12. Thomson S, Figueras J, Evetovits T, Jowett M, Mladovsky P, Cylus J, Karanikolos M, Kluge H.
577 Economic crisis, health systems and health in Europe. Impact and implications for policy (2015).
578 Copenhagen; 2015. World Health Organization. en.
- 579
- 580 13. Sum G, Hone T, Atun R, Millett C, Suhrcke M, Mahal A, Koh GC, Lee JT. Multimorbidity and
581 out-of-pocket expenditure on medicines: a systematic review. *BMJ Glob Health*. 2018;3(1):e000505.
582 Epub 2018/03/23. doi:10.1136/bmjgh-2017-000505. Cited in: Pubmed; PMID 29564155.
- 583
- 584 14. Lee JT, Hamid F, Pati S, Atun R, Millett C. Impact of Noncommunicable Disease Multimorbidity
585 on Healthcare Utilisation and Out-Of-Pocket Expenditures in Middle-Income Countries: Cross
586 Sectional Analysis. *PLoS One*. 2015;10(7):e0127199. eng. Epub 2015/07/15.
587 doi:10.1371/journal.pone.0127199. Cited in: Pubmed; PMID 26154083.
- 588
- 589 15. Safran DG, Neuman P, Schoen C. Prescription drug coverage and seniors: Findings from a 2003
590 national survey. *Health Aff (Millwood)*. 2005;(SUPPL.):W5152-W5166.
- 591
- 592 16. Fu AZ, Jiang JZ, Reeves JH, Fincham JE, Liu GG, Perri M. Potentially inappropriate medication
593 use and healthcare expenditures in the US community-dwelling elderly. *Medical Care*.
594 2007;45(5):472-476. doi:10.1097/01.mlr.0000254571.05722.34.
- 595
- 596 17. Wallace E, Salisbury C, Guthrie B, Lewis C, Fahey T, Smith SM. Managing patients with
597 multimorbidity in primary care. *BMJ (Online)*. 2015;350. doi:10.1136/bmj.h176.
- 598

Multimorbidity and out-of-pocket expenditure on medicine in Europe

- 599 18. OECD. Country Health Profile 2021. 2021 20/11/2022. Available from:
600 <https://www.oecd.org/health/country-health-profiles-eu.htm>.
- 601
- 602 19. Börsch-Supan A, Brandt M, Hunkler C, Kneip T, Korbmacher J, Malter F, Schaan B, Stuck S,
603 Zuber S. Data resource profile: The survey of health, ageing and retirement in europe (share).
604 International Journal of Epidemiology. 2013;42(4):992-1001. doi:10.1093/ije/dyt088.
- 605
- 606 20. Larraga L, Saz P, E DM, G M, A L. A validation of the Spanish version of the EURO-D scale" an
607 instrument for detecting depression in older people. Int J Geriatr Psychiatry. 2006;21:1199-1205.
- 608
- 609 21. Harrison C, Henderson J, Miller G, Britt H. The prevalence of complex multimorbidity in
610 Australia. Aust N Z J Public Health. 2016 Jun;40(3):239-44. Epub 2016/03/31. doi:10.1111/1753-
611 6405.12509. Cited in: Pubmed; PMID 27027989.
- 612
- 613 22. Vinjerui KH, Bjerkeset O, Bjorngaard JH, Krokstad S, Douglas KA, Sund ER. Socioeconomic
614 inequalities in the prevalence of complex multimorbidity in a Norwegian population: findings from
615 the cross-sectional HUNT Study. BMJ Open. 2020 Jun 15;10(6):e036851. Epub 2020/06/18.
616 doi:10.1136/bmjopen-2020-036851. Cited in: Pubmed; PMID 32546494.
- 617
- 618 23. Anderson L, Campbell-Sills L, Ursano RJ, Kessler RC, Sun XY, Heeringa SG, Nock MK, Bliese
619 PD, Gonzalez OI, Wynn GH, Jain S, Stein MB. Prospective associations of perceived unit cohesion
620 with postdeployment mental health outcomes. *Depress Anxiety*. 2019 Jun;36(6):511-521. English.
621 doi:10.1002/da.22884. Cited in: Pubmed; PMID WOS:000470715500004.
- 622
- 623 24. Jones A. Models For Health Care. 2010. HEDG, c/o Department of Economics, University of
624 York.
- 625
- 626 25. Deb P, Norton EC. Modeling Health Care Expenditures and Use. *Annu Rev Public Health*. 2018
627 Apr 1;39:489-505. Epub 2018/01/13. doi:10.1146/annurev-publhealth-040617-013517. Cited in:
628 Pubmed; PMID 29328879.
- 629
- 630 26. Belotti F, Deb P, Manning W, Norton E. twopm: Two-part models. *Stata Journal*. 2015;15(1):3-
631 20.
- 632
- 633 27. Deb P, Norton EC, Manning WG, Press S. *Health Econometrics Using Stata*. Stata Press; 2017.
634 ISBN: 9781597182294. <https://books.google.co.uk/books?id=hlC5uQEACAAJ>.

635

636 28. Hill SC, Miller GE. Health expenditure estimation and functional form: applications of the
637 generalized gamma and extended estimating equations models. *Health Econ.* 2010 May;19(5):608-
638 27. Epub 2009/05/13. doi:10.1002/hec.1498. Cited in: Pubmed; PMID 19434646.

639

640 29. Wooldridge JM. *Econometric Analysis of Cross Section and Panel Data*, second edition. MIT
641 Press; 2010. ISBN: 9780262232586. <https://books.google.fr/books?id=yov6AQAAQBAJ>.

642

643 30. Deb P, Trivedi PK, Zimmer DM. Cost-offsets of prescription drug expenditures: data analysis via
644 a copula-based bivariate dynamic hurdle model. *Health Econ.* 2014 Oct;23(10):1242-59. Epub
645 2013/08/21. doi:10.1002/hec.2982. Cited in: Pubmed; PMID 23956147.

646

647 31. Palladino R, Tayu Lee J, Ashworth M, Triassi M, Millett C. Associations between
648 multimorbidity, healthcare utilisation and health status: evidence from 16 European countries. *Age*
649 *Ageing.* 2016 May;45(3):431-5. eng. Epub 2016/03/26. doi:10.1093/ageing/afw044. Cited in:
650 Pubmed; PMID 27013499.

651

652 32. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity
653 and implications for health care, research, and medical education: A cross-sectional study. *The*
654 *Lancet.* 2012;380(9836):37-43. doi:10.1016/S0140-6736(12)60240-2.

655

656 33. National Institute for Health and Care Excellence. *Multimorbidity: clinical assessment and*
657 *management.* London, UK: National Institute for Health and Care Excellence; 2016. 2018.
658 01/04/2018.

659

660 34. Katie Palmer, Alessandra Marengoni, Elena Jureviciene, Tiina Laatikainen, Federica
661 Mammarella, Christiane Muth, Sandra Prados-Torres, Mieke Rijken, Ulrike Rothe, Jose Valderas,
662 Theodore Vontetsianos, Jelka Zaletel, Joao Forjaz, Laurène Souchet, Rokas Navickas, Graziano
663 Onder. *Multimorbidity care model: Recommendations from the consensus meeting of the Joint*
664 *Action on Chronic.* 2016. CHRODIS.

665

666 35. Rijken M, Hujala A, van Ginneken E, Melchiorre MG, Groenewegen P, Schellevis F. Managing
667 multimorbidity: Profiles of integrated care approaches targeting people with multiple chronic
668 conditions in Europe. *Health Policy.* 2018 Jan;122(1):44-52. eng. Epub 2017/11/06.
669 doi:10.1016/j.healthpol.2017.10.002. Cited in: Pubmed; PMID 29102089.

670

671 36. Grund S, Gordon AL, Bauer JM, Achterberg WP, Schols J. The COVID rehabilitation paradox:
672 why we need to protect and develop geriatric rehabilitation services in the face of the pandemic. *Age*

Multimorbidity and out-of-pocket expenditure on medicine in Europe

673 Ageing. 2021 May 5;50(3):605-607. Epub 2021/01/15. doi:10.1093/ageing/afab009. Cited in:
674 Pubmed; PMID 33443544.

675

676 37. Wagstaff A, Flores G, Hsu J, Smitz MF, Chepynoga K, Buisman LR, van Wilgenburg K,
677 Eozenou P. Progress on catastrophic health spending in 133 countries: a retrospective observational
678 study. Lancet Glob Health. 2018 Feb;6(2):e169-e179. Epub 2017/12/19. doi:10.1016/S2214-
679 109X(17)30429-1. Cited in: Pubmed; PMID 29248367.

680

681